Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Goodwill & Intangibles (2021 - 2025)

Indivior Pharmaceuticals has reported Goodwill & Intangibles over the past 5 years, most recently at $2.0 million for Q4 2025.

  • Quarterly results put Goodwill & Intangibles at $2.0 million for Q4 2025, down 66.67% from a year ago — trailing twelve months through Dec 2025 was $2.0 million (down 66.67% YoY), and the annual figure for FY2025 was $2.0 million, down 66.67%.
  • Goodwill & Intangibles for Q4 2025 was $2.0 million at Indivior Pharmaceuticals, roughly flat from $2.0 million in the prior quarter.
  • Over the last five years, Goodwill & Intangibles for INDV hit a ceiling of $82.0 million in Q4 2021 and a floor of $2.0 million in Q1 2024.
  • Median Goodwill & Intangibles over the past 5 years was $7.0 million (2025), compared with a mean of $21.2 million.
  • Biggest five-year swings in Goodwill & Intangibles: tumbled 81.43% in 2023 and later soared 250.0% in 2025.
  • Indivior Pharmaceuticals' Goodwill & Intangibles stood at $82.0 million in 2021, then dropped by 14.63% to $70.0 million in 2022, then tumbled by 81.43% to $13.0 million in 2023, then tumbled by 53.85% to $6.0 million in 2024, then crashed by 66.67% to $2.0 million in 2025.
  • The last three reported values for Goodwill & Intangibles were $2.0 million (Q4 2025), $2.0 million (Q3 2025), and $7.0 million (Q2 2025) per Business Quant data.